» Articles » PMID: 23221552

Design Requirements for Interfering Particles to Maintain Coadaptive Stability with HIV-1

Overview
Journal J Virol
Date 2012 Dec 11
PMID 23221552
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Defective interfering particles (DIPs) are viral deletion mutants lacking essential transacting or packaging elements and must be complemented by wild-type virus to propagate. DIPs transmit through human populations, replicating at the expense of the wild-type virus and acting as molecular parasites of viruses. Consequently, engineered DIPs have been proposed as therapies for a number of diseases, including human immunodeficiency virus (HIV). However, it is not clear if DIP-based therapies would face evolutionary blocks given the high mutation rates and high within-host diversity of lentiviruses. Divergent evolution of HIV and DIPs appears likely since natural DIPs have not been detected for lentiviruses, despite extensive sequencing of HIVs and simian immunodeficiency viruses (SIVs). Here, we tested if the apparent lack of lentiviral DIPs is due to natural selection and analyzed which molecular characteristics a DIP or DIP-based therapy would need to maintain coadaptive stability with HIV-1. Using a well-established mathematical model of HIV-1 in a host extended to include its replication in a single cell and interference from DIP, we calculated evolutionary selection coefficients. The analysis predicts that interference by codimerization between DIPs and HIV-1 genomes is evolutionarily unstable, indicating that recombination between DIPs and HIV-1 would be selected against. In contrast, DIPs that interfere via competition for capsids have the potential to be evolutionarily stable if the capsid-to-genome production ratio of HIV-1 is >1. Thus, HIV-1 variants that attempt to "starve" DIPs to escape interference would be selected against. In summary, the analysis suggests specific experimental measurements that could address the apparent lack of naturally occurring lentiviral DIPs and specifies how therapeutic approaches based on engineered DIPs could be evolutionarily robust and avoid recombination.

Citing Articles

Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.

Pitchai F, Tanner E, Khetan N, Vasen G, Levrel C, Kumar A Science. 2024; 385(6709):eadn5866.

PMID: 39116226 PMC: 11545966. DOI: 10.1126/science.adn5866.


Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies.

Rouzine I, Rozhnova G Commun Med (Lond). 2023; 3(1):86.

PMID: 37336956 PMC: 10279745. DOI: 10.1038/s43856-023-00320-x.


Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study.

Fatehi F, Bingham R, Dechant P, Stockley P, Twarock R Sci Rep. 2021; 11(1):23847.

PMID: 34903795 PMC: 8668974. DOI: 10.1038/s41598-021-03168-0.


Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.

Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A Cell. 2021; 184(25):6022-6036.e18.

PMID: 34838159 PMC: 8577993. DOI: 10.1016/j.cell.2021.11.004.


Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome.

Shirogane Y, Rousseau E, Voznica J, Xiao Y, Su W, Catching A PLoS Pathog. 2021; 17(9):e1009277.

PMID: 34570820 PMC: 8496841. DOI: 10.1371/journal.ppat.1009277.


References
1.
Marriott A, Dimmock N . Defective interfering viruses and their potential as antiviral agents. Rev Med Virol. 2009; 20(1):51-62. DOI: 10.1002/rmv.641. View

2.
Kirkwood T, Bangham C . Cycles, chaos, and evolution in virus cultures: a model of defective interfering particles. Proc Natl Acad Sci U S A. 1994; 91(18):8685-9. PMC: 44671. DOI: 10.1073/pnas.91.18.8685. View

3.
Giachetti C, Holland J . Altered replicase specificity is responsible for resistance to defective interfering particle interference of an Sdi- mutant of vesicular stomatitis virus. J Virol. 1988; 62(10):3614-21. PMC: 253502. DOI: 10.1128/JVI.62.10.3614-3621.1988. View

4.
Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb J . A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet. 2011; 43(5):487-9. DOI: 10.1038/ng.795. View

5.
Bukovsky A, Song J, Naldini L . Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol. 1999; 73(8):7087-92. PMC: 112802. DOI: 10.1128/JVI.73.8.7087-7092.1999. View